Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Androderm® Clear all
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

NCT00141557
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants

NCT04320745
View directory record Official record
Conditions
Hypogonadism
Interventions
Androderm®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations

NCT00857454
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Tuscon, Arizona • Burbank, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 4 Interventional

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331
View directory record Official record
Conditions
Peyronie's Disease (PD)
Interventions
Xiaflex®, Aveed
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650
View directory record Official record
Conditions
Hypogonadism
Interventions
Nasobol®, Androderm® (Positive Control)
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 21, 2026, 12:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

NCT00857961
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Tuscon, Arizona • Burbank, California • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

NCT06385509
View directory record Official record
Conditions
Hypogonadism
Interventions
Jatenzo Oral Product
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 12:22 PM EDT
Withdrawn Phase 4 Interventional

Testosterone and Pain Sensitivity

NCT01689896
View directory record Official record
Conditions
Low Testosterone, Hypogonadism, Pain
Interventions
Testosterone Gel, Placebo Gel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Axiron® in Healthy Participants

NCT02004132
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Axiron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

NCT02159469
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 21, 2026, 12:22 PM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

NCT00141544
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT02233751
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

NCT00962637
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 21, 2026, 12:22 PM EDT
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

NCT02777242
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 21, 2026, 12:22 PM EDT
Recruiting Phase 3 Interventional

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

NCT06689085
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone enanthate
Combination Product
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
12 Years to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 1 Interventional

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

NCT02504541
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 21, 2026, 12:22 PM EDT
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 21, 2026, 12:22 PM EDT
Completed Phase 2 Interventional

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

NCT00141570
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
77
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 21, 2026, 12:22 PM EDT